S&P 500   3,617.46 (-0.57%)
DOW   29,566.29 (-1.15%)
QQQ   299.16 (+0.05%)
AAPL   120.54 (+3.39%)
MSFT   212.68 (-1.18%)
FB   275.87 (-0.70%)
GOOGL   1,755.11 (-1.79%)
AMZN   3,164.59 (-0.96%)
TSLA   579.92 (-1.00%)
NVDA   532.16 (+0.32%)
BABA   264.29 (-4.41%)
CGC   28.78 (-0.76%)
GE   10.27 (-1.25%)
MU   64.24 (+0.02%)
AMD   92.37 (+5.94%)
T   28.77 (-0.90%)
NIO   51.47 (-4.69%)
F   9.12 (+0.33%)
ACB   11.71 (+11.84%)
NFLX   488.34 (-0.61%)
BA   211.68 (-2.23%)
GILD   59.90 (-0.22%)
DIS   147.44 (+0.21%)
S&P 500   3,617.46 (-0.57%)
DOW   29,566.29 (-1.15%)
QQQ   299.16 (+0.05%)
AAPL   120.54 (+3.39%)
MSFT   212.68 (-1.18%)
FB   275.87 (-0.70%)
GOOGL   1,755.11 (-1.79%)
AMZN   3,164.59 (-0.96%)
TSLA   579.92 (-1.00%)
NVDA   532.16 (+0.32%)
BABA   264.29 (-4.41%)
CGC   28.78 (-0.76%)
GE   10.27 (-1.25%)
MU   64.24 (+0.02%)
AMD   92.37 (+5.94%)
T   28.77 (-0.90%)
NIO   51.47 (-4.69%)
F   9.12 (+0.33%)
ACB   11.71 (+11.84%)
NFLX   488.34 (-0.61%)
BA   211.68 (-2.23%)
GILD   59.90 (-0.22%)
DIS   147.44 (+0.21%)
S&P 500   3,617.46 (-0.57%)
DOW   29,566.29 (-1.15%)
QQQ   299.16 (+0.05%)
AAPL   120.54 (+3.39%)
MSFT   212.68 (-1.18%)
FB   275.87 (-0.70%)
GOOGL   1,755.11 (-1.79%)
AMZN   3,164.59 (-0.96%)
TSLA   579.92 (-1.00%)
NVDA   532.16 (+0.32%)
BABA   264.29 (-4.41%)
CGC   28.78 (-0.76%)
GE   10.27 (-1.25%)
MU   64.24 (+0.02%)
AMD   92.37 (+5.94%)
T   28.77 (-0.90%)
NIO   51.47 (-4.69%)
F   9.12 (+0.33%)
ACB   11.71 (+11.84%)
NFLX   488.34 (-0.61%)
BA   211.68 (-2.23%)
GILD   59.90 (-0.22%)
DIS   147.44 (+0.21%)
S&P 500   3,617.46 (-0.57%)
DOW   29,566.29 (-1.15%)
QQQ   299.16 (+0.05%)
AAPL   120.54 (+3.39%)
MSFT   212.68 (-1.18%)
FB   275.87 (-0.70%)
GOOGL   1,755.11 (-1.79%)
AMZN   3,164.59 (-0.96%)
TSLA   579.92 (-1.00%)
NVDA   532.16 (+0.32%)
BABA   264.29 (-4.41%)
CGC   28.78 (-0.76%)
GE   10.27 (-1.25%)
MU   64.24 (+0.02%)
AMD   92.37 (+5.94%)
T   28.77 (-0.90%)
NIO   51.47 (-4.69%)
F   9.12 (+0.33%)
ACB   11.71 (+11.84%)
NFLX   488.34 (-0.61%)
BA   211.68 (-2.23%)
GILD   59.90 (-0.22%)
DIS   147.44 (+0.21%)
Log in
NASDAQ:RUBY

Rubius Therapeutics Stock Forecast, Price & News

$6.25
-0.60 (-8.76 %)
(As of 11/30/2020 03:21 PM ET)
Add
Compare
Today's Range
$6.25
Now: $6.25
$6.70
50-Day Range
$4.23
MA: $5.06
$6.54
52-Week Range
$3.35
Now: $6.25
$14.44
Volume7,312 shs
Average Volume296,244 shs
Market Capitalization$505.78 million
P/E RatioN/A
Dividend YieldN/A
Beta1.99
Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Read More
Rubius Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.73 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RUBY
CUSIPN/A
CIKN/A
Phone617-679-9600
Employees199

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.44 per share

Profitability

Net Income$-163,460,000.00

Miscellaneous

Market Cap$505.78 million
Next Earnings Date3/11/2021 (Estimated)
OptionableNot Optionable
$6.25
-0.60 (-8.76 %)
(As of 11/30/2020 03:21 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RUBY News and Ratings via Email

Sign-up to receive the latest news and ratings for RUBY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Rubius Therapeutics (NASDAQ:RUBY) Frequently Asked Questions

How has Rubius Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Rubius Therapeutics' stock was trading at $6.55 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RUBY shares have decreased by 2.0% and is now trading at $6.42.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Rubius Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rubius Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Rubius Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Rubius Therapeutics?

Wall Street analysts have given Rubius Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Rubius Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Rubius Therapeutics' next earnings date?

Rubius Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 11th 2021.
View our earnings forecast for Rubius Therapeutics
.

How were Rubius Therapeutics' earnings last quarter?

Rubius Therapeutics, Inc. (NASDAQ:RUBY) posted its earnings results on Monday, November, 9th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.50) by $0.01.
View Rubius Therapeutics' earnings history
.

What price target have analysts set for RUBY?

5 equities research analysts have issued 12-month target prices for Rubius Therapeutics' shares. Their forecasts range from $4.00 to $28.00. On average, they expect Rubius Therapeutics' share price to reach $11.40 in the next year. This suggests a possible upside of 77.6% from the stock's current price.
View analysts' price targets for Rubius Therapeutics
.

Who are some of Rubius Therapeutics' key competitors?

What other stocks do shareholders of Rubius Therapeutics own?

Who are Rubius Therapeutics' key executives?

Rubius Therapeutics' management team includes the following people:
  • Mr. David R. Epstein, Exec. Chairman (Age 58, Pay $495k)
  • Dr. Pablo J. Cagnoni, CEO, Pres & Director (Age 57, Pay $785.88k)
  • Ms. Maiken Keson-Brookes, Chief Legal Officer & Corp. Sec. (Age 47, Pay $190.17k)
  • Mr. Jose Carmona, CFO, Principal Accounting Officer & Treasurer (Age 48)
  • Ms. Joanne M. Protano, Sr. VP of Fin. & Operations (Age 51)
  • Mr. Spencer Fisk, Sr. VP & Chief Technical Operations Officer
  • Mr. Laurence A. Turka M.D., Chief Scientific Officer (Age 62)
  • Ms. Lori Melancon, VP of Corp. Communications & Investor Relations
  • Mr. Theo Proukou, Sr. VP & Chief People Officer
  • Mr. Greg Whitehead, Sr. VP & Chief Quality Officer

When did Rubius Therapeutics IPO?

(RUBY) raised $200 million in an initial public offering on Wednesday, July 18th 2018. The company issued 9,500,000 shares at $20.00-$22.00 per share. J.P. Morgan, Morgan Stanley, Jefferies and Leerink Partners served as the underwriters for the IPO.

What is Rubius Therapeutics' stock symbol?

Rubius Therapeutics trades on the NASDAQ under the ticker symbol "RUBY."

Who are Rubius Therapeutics' major shareholders?

Rubius Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.07%), JPMorgan Chase & Co. (2.85%), State Street Corp (0.84%), Charles Schwab Investment Management Inc. (0.29%), California Public Employees Retirement System (0.09%) and Arrowstreet Capital Limited Partnership (0.07%). Company insiders that own Rubius Therapeutics stock include Christina M Coughlin, Christopher L Carpenter, David R Epstein, Pablo J Cagnoni, Robert Langer and Torben Straight Nissen.
View institutional ownership trends for Rubius Therapeutics
.

Which major investors are selling Rubius Therapeutics stock?

RUBY stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, BlackRock Inc., SG Americas Securities LLC, UBS Asset Management Americas Inc., State Street Corp, Virtus ETF Advisers LLC, Aperio Group LLC, and Great West Life Assurance Co. Can.
View insider buying and selling activity for Rubius Therapeutics
.

Which major investors are buying Rubius Therapeutics stock?

RUBY stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Jane Street Group LLC, DekaBank Deutsche Girozentrale, Squarepoint Ops LLC, Paloma Partners Management Co, Schonfeld Strategic Advisors LLC, Schonfeld Strategic Advisors LLC, and Public Employees Retirement System of Ohio. Company insiders that have bought Rubius Therapeutics stock in the last two years include Christina M Coughlin, David R Epstein, and Pablo J Cagnoni.
View insider buying and selling activity for Rubius Therapeutics
.

How do I buy shares of Rubius Therapeutics?

Shares of RUBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Rubius Therapeutics' stock price today?

One share of RUBY stock can currently be purchased for approximately $6.42.

How big of a company is Rubius Therapeutics?

Rubius Therapeutics has a market capitalization of $519.53 million. The company earns $-163,460,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis. Rubius Therapeutics employs 199 workers across the globe.

What is Rubius Therapeutics' official website?

The official website for Rubius Therapeutics is www.rubiustx.com.

How can I contact Rubius Therapeutics?

Rubius Therapeutics' mailing address is 399 BINNEY STREET SUITE 300, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-679-9600 or via email at [email protected]

This page was last updated on 11/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.